[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 10
1. Nishimura Y, Satoh T, Adachi H, Kondo S, Takeuchi T, Azetaka M, Fukuyasu H, Iizuka Y: Synthesis and antimetastatic activity of L-iduronic acid-type 1-N-iminosugars. J Med Chem; 1997 Aug 1;40(16):2626-33
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • L-Iduronic acid-type 1-N-iminosugars, (3R,4S,5R,6R)- and (3R,4S,5S,6R)-6-acetamido-4-amino-5-hydroxypiperidine-3-carboxylic acid (6 and 7, respectively), (3R,4S,5R,6R)-6-acetamido-4- guanidino-5-hydroxypiperidine-3-carboxylic acid (8), and (3R,4S,5R,6R)-4-amino- and -guanidino-5-hydroxy-6-(trifluoroacetamido) piperidine-3-carboxylic acid (9 and 10, respectively), were synthesized from siastatin B (1), isolated from Streptomyces culture, by the intramolecular Michael addition of O-imidate to its alpha,beta-unsaturated ester through cis oxiamination as a key step.
  • Pulmonary metastasis of B16 BL6 cells in mice was remarkably inhibited by pretreatment of the cells with these compounds in culture.
  • [MeSH-major] Antineoplastic Agents / chemical synthesis. Iduronic Acid / analogs & derivatives
  • [MeSH-minor] Animals. Enzyme Inhibitors / chemistry. Enzyme Inhibitors / pharmacology. Lung Neoplasms / secondary. Mice. Models, Chemical. Neoplasm Metastasis / prevention & control. Piperidines / chemistry. Piperidines / pharmacology. Structure-Activity Relationship. Tumor Cells, Cultured

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 9258369.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 0 / Piperidines; 3402-98-0 / Iduronic Acid; 56573-74-1 / siastatin
  •  go-up   go-down


2. Minamimoto R, Hancock S, Schneider B, Chin FT, Jamali M, Loening A, Vasanawala S, Gambhir SS, Iagaru A: Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer. J Nucl Med; 2016 Apr;57(4):557-62
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pilot Comparison of ⁶⁸Ga-RM2 PET and ⁶⁸Ga-PSMA-11 PET in Patients with Biochemically Recurrent Prostate Cancer.
  • Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)] ((68)Ga-PSMA-11) is a PET tracer that can detect prostate cancer relapses and metastases by binding to the extracellular domain of PSMA. (68)Ga-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 ((68)Ga-RM2) is a synthetic bombesin receptor antagonist that targets gastrin-releasing peptide receptors.
  • We present pilot data on the biodistribution of these PET tracers in a small cohort of patients with biochemically recurrent prostate cancer.
  • METHODS: Seven men (mean age ± SD, 74.3 ± 5.9 y) with biochemically recurrent prostate cancer underwent both (68)Ga-PSMA-11 PET/CT and (68)Ga-RM2 PET/MRI scans.
  • CONCLUSION: (68)Ga-PSMA-11 and (68)Ga-RM2 had distinct biodistributions in this small cohort of patients with biochemically recurrent prostate cancer.
  • Additional work is needed to understand the expression of PSMA and gastrin-releasing peptide receptors in different types of prostate cancer.
  • [MeSH-major] Neoplasm Recurrence, Local / radionuclide imaging. Oligopeptides. Organometallic Compounds. Positron-Emission Tomography / methods. Prostate-Specific Antigen / metabolism. Prostatic Neoplasms / radionuclide imaging. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer Screening.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2016 by the Society of Nuclear Medicine and Molecular Imaging, Inc.
  • (PMID = 26659347.001).
  • [ISSN] 1535-5667
  • [Journal-full-title] Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • [ISO-abbreviation] J. Nucl. Med.
  • [Language] eng
  • [Databank-accession-numbers] ClinicalTrials.gov/ NCT02440308/ NCT02488070
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / (68Ga)Glu-urea-Lys(Ahx)-HBED-CC; 0 / BAY 86-7548; 0 / Oligopeptides; 0 / Organometallic Compounds; 0 / Radiopharmaceuticals; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Keywords] NOTNLM ; 68Ga / PET/CT / PET/MRI / PSMA / RM2 / prostate cancer
  •  go-up   go-down


3. Deng YQ, Zhou XH, Jiang LL, Tang XJ, Zhang YX, Cui JQ: [Clinical significance of σ1 receptor over-expression in cervical cancer and the effect of its synthetic ligands on the growth of cervical cancer cells]. Zhonghua Fu Chan Ke Za Zhi; 2017 Jul 25;52(7):473-482
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of σ1 receptor over-expression in cervical cancer and the effect of its synthetic ligands on the growth of cervical cancer cells].
  • <b>Objective:</b> To explore the role of σ1 receptor (σ1R) in the clinical prognosis of cervical cancer,and provide a theoretical basis for σ1R targeted molecular therapy through observing the inhibition of synthetic σ1R-specific ligand compounds on the growth of cervical cancer cells.
  • <b>Methods:</b> (1) Immunohistochemical or immunocytochemistry staining were respectively used to detect the expression and localization of σ1R protein. (2) The Cancer Genome Atlas (TCGA) data set was used to validate our results. (3) Two series of 4 novel σ1R ligand compounds were synthesized by altering the N-terminal substituents on the piperidine ring of the prezamicol analogue, named as 14a, 14e, 15c and 15f.
  • σ1R expression in AC was significantly associated with advanced stage, lymphnode metastasis and vascular invasion (all <i>P<</i>0.05).
  • <b>Conclusions:</b> σ1R is over-expressed in cervical cancer and HSIL.
  • σ1R over-expression, especially σ1R nuclear expression is associated with the poor prognosis of cervical cancer.
  • Our study is mostly consistent with cervical cancer data of TCGA.
  • These results suggest that the novel synthetic prezamicol analogues 14a for σ1R could inhibit the growth of cervical cancer cells and cell migration through inducing apoptosis and arresting cell cycle in G(0)/G(1) period, enhance NDP-induced cytotoxicity.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28797155.001).
  • [ISSN] 0529-567X
  • [Journal-full-title] Zhonghua fu chan ke za zhi
  • [ISO-abbreviation] Zhonghua Fu Chan Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Keywords] NOTNLM ; Cell line, tumor / HeLa cells / Piperidines / Receptors, sigma / Uterine cervical neoplasms
  •  go-up   go-down


Advertisement
4. Thimmaiah KN, Horton JK, Seshadri R, Israel M, Houghton JA, Harwood FC, Houghton PJ: Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells. J Med Chem; 1992 Sep 4;35(18):3358-64
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synthesis and chemical characterization of N-substituted phenoxazines directed toward reversing vinca alkaloid resistance in multidrug-resistant cancer cells.
  • A series of 21 N-substituted phenoxazines has been synthesized in an effort to find more specific and less toxic modulators of multidrug resistance (MDR) in cancer chemotherapy.
  • Thus, N-(omega-chloroalkyl)- and N-(chloroacyl)phenoxazines were found to undergo iodide-catalyzed nucleophilic substitution on reaction with various secondary amines, including N,N-diethylamine, N,N-diethanolamine, morpholine, piperidine, pyrrolidine and (beta-hydroxyethyl)piperazine.
  • [MeSH-major] Drug Resistance. Oxazines / chemical synthesis. Vinca Alkaloids / pharmacology
  • [MeSH-minor] Humans. Structure-Activity Relationship. Tumor Cells, Cultured / drug effects

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 1527786.001).
  • [ISSN] 0022-2623
  • [Journal-full-title] Journal of medicinal chemistry
  • [ISO-abbreviation] J. Med. Chem.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA-21765; United States / NCI NIH HHS / CA / CA-23099; United States / NCI NIH HHS / CA / CA-40570
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Oxazines; 0 / Vinca Alkaloids; 135-67-1 / phenoxazine
  •  go-up   go-down


5. Delaney S, Delaney JC, Essigmann JM: Chemical-biological fingerprinting: probing the properties of DNA lesions formed by peroxynitrite. Chem Res Toxicol; 2007 Nov;20(11):1718-29
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemical-biological fingerprinting: probing the properties of DNA lesions formed by peroxynitrite.
  • Analysis of these lesions from the structural and biological viewpoints is often complicated by the reality that some of the lesions are chemically fragile, leading to an even larger set of secondary and tertiary products.
  • In an effort to deconvolute complex DNA-damage spectra, a strategy is presented whereby an oligonucleotide containing a specific target for chemical reaction is allowed to react with a DNA-damaging agent.
  • A large collection of HPLC-resolvable modified oligonucleotides is generated, and chromatographically distinct members of the set are then individually characterized using chemical, spectroscopic, biochemical, and genetic probes.
  • The biological component of this "chemical-biological fingerprinting" tool is the use of polymerase bypass in vivo in cells having defined replication status and quantitative and qualitative patterns of lesion-directed mutagenesis, as key properties that complement physical analysis of modified DNA.
  • Using mass spectrometry, coelution with authentic standards, sensitivity to piperidine, recognition and strand cleavage by the DNA repair enzyme MutM, and mutagenicity and genotoxicity in vivo, a matrix was created that defined the properties of the secondary DNA lesions formed when 3-morpholinosydnonimine (SIN-1) delivered a low, constant flux of peroxynitrite to an oligonucleotide containing 8-oxoGua.
  • However, in addition to these lesions, a number of secondary lesions were generated that had chemical-biological fingerprints inconsistent with that of any known 8-oxoGua-derived lesion described to date.
  • In vitro experiments showed that while some of these newly characterized secondary lesions were removed from DNA by MutM, others were in fact very poor substrates for this repair enzyme.
  • These 8-oxoGua-derived lesions also showed varying degrees of sensitivity to piperidine.
  • Furthermore, all of the secondary lesions observed in this work were potently mutagenic and genotoxic in Escherichia coli.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. GUANINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Biochem Biophys. 1995 Oct 1;322(2):500-5 [7574726.001]
  • [Cites] Carcinogenesis. 1995 Sep;16(9):2045-50 [7554052.001]
  • [Cites] Biochemistry. 1996 Jun 18;35(24):7855-61 [8672486.001]
  • [Cites] Free Radic Res. 1996 May;24(5):369-80 [8733941.001]
  • [Cites] Arch Biochem Biophys. 1996 Sep 1;333(1):49-58 [8806753.001]
  • [Cites] Mutat Res. 2000 Feb 14;447(2):287-303 [10751613.001]
  • [Cites] Chem Res Toxicol. 2000 May;13(5):390-6 [10813656.001]
  • [Cites] Org Lett. 2000 Mar 9;2(5):613-6 [10814391.001]
  • [Cites] Chem Res Toxicol. 2000 Jul;13(7):658-64 [10898599.001]
  • [Cites] Biochemistry. 2000 Dec 5;39(48):14984-92 [11101315.001]
  • [Cites] Chem Res Toxicol. 2001 Jan;14(1):46-53 [11170507.001]
  • [Cites] Org Lett. 2001 Apr 5;3(7):963-6 [11277770.001]
  • [Cites] Chem Biol. 2001 Apr;8(4):369-78 [11325592.001]
  • [Cites] J Am Chem Soc. 2001 Jun 27;123(25):5867-77 [11414819.001]
  • [Cites] Chem Res Toxicol. 2001 Jul;14(7):927-38 [11453741.001]
  • [Cites] J Am Chem Soc. 2001 Dec 12;123(49):12147-51 [11734012.001]
  • [Cites] Biochemistry. 2002 Jan 22;41(3):914-21 [11790114.001]
  • [Cites] Chem Res Toxicol. 2002 Apr;15(4):591-7 [11952346.001]
  • [Cites] Mutat Res. 2002 May 22;502(1-2):11-8 [11996967.001]
  • [Cites] Biochemistry. 2002 Jun 11;41(23):7508-18 [12044185.001]
  • [Cites] Nucleic Acids Res. 2001 May 1;29(9):1967-74 [11328881.001]
  • [Cites] Biochemistry. 2002 Dec 24;41(51):15304-14 [12484769.001]
  • [Cites] Nat Rev Cancer. 2003 Apr;3(4):276-85 [12671666.001]
  • [Cites] Biochemistry. 2003 Aug 12;42(31):9257-62 [12899611.001]
  • [Cites] Chem Res Toxicol. 2003 Aug;16(8):966-73 [12924924.001]
  • [Cites] Org Biomol Chem. 2003 Dec 21;1(24):4451-7 [14727638.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43568-73 [15299010.001]
  • [Cites] Nucleic Acids Res. 2004;32(18):5480-5 [15477395.001]
  • [Cites] J Org Chem. 1974 Jul 12;39(14):1983-9 [4846180.001]
  • [Cites] Biochemistry. 1990 Jul 31;29(30):7024-32 [2223758.001]
  • [Cites] Mutat Res. 1991 Jan;254(1):1-12 [1986271.001]
  • [Cites] Free Radic Biol Med. 1996;21(3):407-11 [8855454.001]
  • [Cites] FEBS Lett. 1996 Dec 9;399(1-2):67-70 [8980121.001]
  • [Cites] Chem Res Toxicol. 1997 Apr;10(4):386-92 [9114974.001]
  • [Cites] Carcinogenesis. 1999 Jan;20(1):167-72 [9934865.001]
  • [Cites] Chem Res Toxicol. 1999 May;12(5):459-66 [10328757.001]
  • [Cites] Chem Res Toxicol. 1999 Jun;12(6):513-20 [10368314.001]
  • [Cites] Chem Res Toxicol. 1999 Jul;12(7):630-8 [10409403.001]
  • [Cites] Chem Res Toxicol. 2004 Nov;17(11):1501-9 [15540948.001]
  • [Cites] Chem Res Toxicol. 2004 Nov;17(11):1510-9 [15540949.001]
  • [Cites] Chem Res Toxicol. 2005 Jan;18(1):12-8 [15651843.001]
  • [Cites] Chem Res Toxicol. 2005 Jan;18(1):76-86 [15651852.001]
  • [Cites] Free Radic Biol Med. 2005 Jun 1;38(11):1491-500 [15890623.001]
  • [Cites] Chem Res Toxicol. 2005 Sep;18(9):1378-83 [16167829.001]
  • [Cites] Nat Struct Mol Biol. 2005 Oct;12(10):855-60 [16200073.001]
  • [Cites] Nitric Oxide. 2006 Mar;14(2):109-21 [16352449.001]
  • [Cites] Chem Res Toxicol. 2006 Apr;19(4):491-505 [16608160.001]
  • [Cites] Methods Enzymol. 2006;408:1-15 [16793359.001]
  • [Cites] Chem Res Toxicol. 2006 Jul;19(7):908-13 [16841958.001]
  • [Cites] Chem Res Toxicol. 2006 Oct;19(10):1357-65 [17040105.001]
  • [Cites] Biochemistry. 2007 Feb 6;46(5):1448-55 [17260974.001]
  • [Cites] J Biol Chem. 2007 Apr 27;282(17):12741-8 [17322566.001]
  • [Cites] Org Lett. 2004 Jan 22;6(2):245-8 [14723539.001]
  • [Cites] Mutat Res. 1991 May;254(3):281-8 [2052015.001]
  • [Cites] Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4690-4 [2052552.001]
  • [Cites] J Biol Chem. 1992 Jan 5;267(1):166-72 [1730583.001]
  • [Cites] Biochemistry. 1992 Nov 17;31(45):10964-8 [1445834.001]
  • [Cites] Nucleic Acids Res. 1993 Jun 25;21(12):2899-905 [8332499.001]
  • [Cites] Free Radic Res Commun. 1993;18(4):195-9 [8396550.001]
  • [Cites] Arch Biochem Biophys. 1995 Jan 10;316(1):327-34 [7840633.001]
  • [Cites] Biochem Biophys Res Commun. 1995 May 25;210(3):1025-30 [7763229.001]
  • [Cites] Nucleic Acids Res. 1995 Oct 11;23(19):3954-61 [7479042.001]
  • (PMID = 17941698.001).
  • [ISSN] 0893-228X
  • [Journal-full-title] Chemical research in toxicology
  • [ISO-abbreviation] Chem. Res. Toxicol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R37 CA080024; United States / NCI NIH HHS / CA / R01 CA080024-09; United States / NCI NIH HHS / CA / CA080024-09; United States / NCI NIH HHS / CA / R01 CA080024-10; United States / NCI NIH HHS / CA / CA26731; United States / NCI NIH HHS / CA / P01 CA026731-250010; United States / NCI NIH HHS / CA / CA026731-260010; United States / NCI NIH HHS / CA / CA080024-10; United States / NCI NIH HHS / CA / P01 CA026731-260010; United States / NCI NIH HHS / CA / P01 CA026731; United States / NCI NIH HHS / CA / CA80024; United States / NCI NIH HHS / CA / R01 CA080024; United States / NCI NIH HHS / CA / CA026731-250010
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / 7,8-dihydro-8-oxoguanine; 14691-52-2 / Peroxynitrous Acid; 5O5U71P6VQ / linsidomine; 5Z93L87A1R / Guanine; D46583G77X / Molsidomine
  • [Other-IDs] NLM/ NIHMS174028; NLM/ PMC2848752
  •  go-up   go-down


6. Kähkönen E, Jambor I, Kemppainen J, Lehtiö K, Grönroos TJ, Kuisma A, Luoto P, Sipilä HJ, Tolvanen T, Alanen K, Silén J, Kallajoki M, Roivainen A, Schäfer N, Schibli R, Dragic M, Johayem A, Valencia R, Borkowski S, Minn H: In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548. Clin Cancer Res; 2013 Oct 1;19(19):5434-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vivo imaging of prostate cancer using [68Ga]-labeled bombesin analog BAY86-7548.
  • PURPOSE: A novel [(68)Ga]-labeled DOTA-4-amino-1-carboxymethyl-piperidine-D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2 peptide (BAY86-7548) having high affinity to bombesin receptor subtype II to detect primary and metastatic prostate carcinoma using positron emission tomography/computed tomography (PET/CT) was synthesized and evaluated for prostate cancer.
  • The visual assessment of PET/CT images included evaluation of intraprostatic (12 subsextants) and pelvic nodal uptake of BAY86-7548 in 11 surgical patients and detection of potential metastatic foci in all patients.
  • RESULTS: We found a sensitivity, specificity, and accuracy of 88%, 81% and 83%, respectively, for detection of primary PCa and sensitivity of 70% for metastatic lymph nodes using histology as gold standard.
  • In the third hormone refractory patient, BAY86-7548 failed to show multiple bone metastases evident on [(18)F]-fluoromethylcholine PET/CT.
  • CONCLUSION: BAY86-7548 PET/CT is a promising molecular imaging technique for detecting intraprostatic prostate cancer.
  • [MeSH-minor] Aged. Aged, 80 and over. Humans. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Recurrence. Reproducibility of Results. Sensitivity and Specificity

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • Zurich Open Access Repository and Archive. Full text from .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2013 AACR.
  • (PMID = 23935037.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Gallium Radioisotopes; PX9AZU7QPK / Bombesin
  •  go-up   go-down


7. Butt MS, Naz A, Sultan MT, Qayyum MM: Anti-oncogenic perspectives of spices/herbs: A comprehensive review. EXCLI J; 2013;12:1043-65
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Promising compounds including curcumin and curcuminoids (turmeric), limonene (cardamom), allicin, allyl isothiocyanate (garlic), cinnamic aldehyde, 2-hydroxycinnamaldehyde and eugenol (cinnamon), gingerol, zingiberone, zingiberene (ginger), dipropyle disulfides and quercetin (onion), piperidine piperine, limonene, α- and β-pinene (black pepper), crocetin, crocin and safranal (saffron) have been identified as chemopreventing agents against various malignancies.
  • Spices phytochemicals have established as carcinogenesis blockers by modulating cell proliferation pathways transformation, inflammation, metastasis etc.
  • The current review is inevitably an affirmative approach in the development of novel guidelines against cancer by using dietary species to maintain good health.

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27092039.001).
  • [ISSN] 1611-2156
  • [Journal-full-title] EXCLI journal
  • [ISO-abbreviation] EXCLI J
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC4827078
  • [Keywords] NOTNLM ; allicin / cinnamic aldehyde / dipropyle disulfides / gingerol / malignancy / piperidine piperine
  •  go-up   go-down


8. Zhang J, Zhu X, Li H, Li B, Sun L, Xie T, Zhu T, Zhou H, Ye Z: Piperine inhibits proliferation of human osteosarcoma cells via G2/M phase arrest and metastasis by suppressing MMP-2/-9 expression. Int Immunopharmacol; 2015 Jan;24(1):50-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Piperine inhibits proliferation of human osteosarcoma cells via G2/M phase arrest and metastasis by suppressing MMP-2/-9 expression.
  • The piperidine alkaloid piperine, a major ingredient in black pepper, inhibits the growth and metastasis of cancer cells both in vivo and in vitro, although its mechanism of action is unclear.
  • In addition, piperine treatment inhibited phosphorylation of Akt and activated phosphorylation of c-Jun N-terminal kinase (c-JNK) and p38 mitogen-activated protein kinase (MAPK) in HOS and U2OS cells.
  • We proved that piperine could suppress the metastasis of osteosarcoma cells using scratch migration assays and Transwell chamber tests.
  • [MeSH-major] Alkaloids / therapeutic use. Benzodioxoles / therapeutic use. Bone Neoplasms / drug therapy. Growth Inhibitors / therapeutic use. Matrix Metalloproteinase 2 / metabolism. Matrix Metalloproteinase 9 / metabolism. Osteosarcoma / drug therapy. Piper nigrum / chemistry. Piperidines / therapeutic use. Polyunsaturated Alkamides / therapeutic use
  • [MeSH-minor] CDC2 Protein Kinase / metabolism. Cell Line, Tumor. Cell Movement. Cell Proliferation / drug effects. Checkpoint Kinase 2 / metabolism. Cyclin B1 / genetics. Cyclin B1 / metabolism. Down-Regulation. Gene Expression Regulation, Neoplastic / drug effects. Humans. M Phase Cell Cycle Checkpoints / drug effects. MAP Kinase Signaling System / drug effects. Neoplasm Metastasis. Tissue Inhibitor of Metalloproteinase-1 / genetics. Tissue Inhibitor of Metalloproteinase-1 / metabolism. Up-Regulation


9. Nishimura Y, Kudo T, Kondo S, Takeuchi T, Tsuruoka T, Fukuyasu H, Shibahara S: Totally synthetic analogues of siastatin B. III. Trifluoroacetamide analogues having inhibitory activity for tumor metastasis. J Antibiot (Tokyo); 1994 Jan;47(1):101-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Totally synthetic analogues of siastatin B. III. Trifluoroacetamide analogues having inhibitory activity for tumor metastasis.
  • A trifluoroacetamide analogue of siastatin B, (3S,4S,5R,6R)-6-(trifluoroacetamido)-4,5-dihydroxy-3-piperidine carboxylic acid has been chemically synthesized.
  • This compound, as well as the previously synthesized analogue, (3R,4R,5R,6R)-6-(trifluoroacetamido)-3,4,5-trihydroxy-3-piperid inecarboxylic acid, showed marked inhibitory activity against beta-glucuronidase and significant inhibition of experimental pulmonary metastasis of the highly metastatic melanoma B16.
  • [MeSH-major] Acetamides / chemical synthesis. Acetamides / therapeutic use. Antineoplastic Agents / chemical synthesis. Antineoplastic Agents / therapeutic use. Glucuronidase / antagonists & inhibitors. Melanoma, Experimental / drug therapy. Piperidines / chemical synthesis. Piperidines / therapeutic use
  • [MeSH-minor] Animals. Glycoside Hydrolases / antagonists & inhibitors. Liver / drug effects. Liver / enzymology. Lung Neoplasms / prevention & control. Male. Mice. Neoplasm Metastasis / prevention & control

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 8119851.001).
  • [ISSN] 0021-8820
  • [Journal-full-title] The Journal of antibiotics
  • [ISO-abbreviation] J. Antibiot.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] JAPAN
  • [Chemical-registry-number] 0 / 6-trifluoroacetamido-4,5-dihydroxy-3-piperidinecarboxylic acid; 0 / Acetamides; 0 / Antineoplastic Agents; 0 / Piperidines; 56573-74-1 / siastatin; EC 3.2.1.- / Glycoside Hydrolases; EC 3.2.1.31 / Glucuronidase
  •  go-up   go-down


10. Kendrick S, Kang HJ, Alam MP, Madathil MM, Agrawal P, Gokhale V, Yang D, Hecht SM, Hurley LH: The dynamic character of the BCL2 promoter i-motif provides a mechanism for modulation of gene expression by compounds that bind selectively to the alternative DNA hairpin structure. J Am Chem Soc; 2014 Mar 19;136(11):4161-71
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The BCL2 promoter region forms two different secondary DNA structures on opposite strands called the G-quadruplex and the i-motif.
  • Here we identify a pregnanol derivative and a class of piperidine derivatives that differentially modulate gene expression by stabilizing either the i-motif or the flexible hairpin species.

  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2009 Oct 1;69(19):7653-61 [19738048.001]
  • [Cites] Nucleic Acids Res. 1996 Dec 15;24(24):5062-3 [9016685.001]
  • [Cites] J Am Chem Soc. 2009 Dec 9;131(48):17667-76 [19908860.001]
  • [Cites] FEBS J. 2010 Mar;277(5):1118-25 [19951354.001]
  • [Cites] Biochemistry. 2010 May 18;49(19):4208-19 [20377208.001]
  • [Cites] Nat Rev Drug Discov. 2010 Jun;9(6):447-64 [20467424.001]
  • [Cites] J Am Chem Soc. 2010 Jul 7;132(26):8991-7 [20545340.001]
  • [Cites] Biophys J. 2010 Jul 21;99(2):561-7 [20643075.001]
  • [Cites] FEBS J. 2010 Sep;277(17):3459-69 [20670278.001]
  • [Cites] Mol Cancer Ther. 2009 May;8(5):1363-77 [19435876.001]
  • [Cites] Nat Rev Drug Discov. 2011 Apr;10(4):261-75 [21455236.001]
  • [Cites] J Am Chem Soc. 2011 Oct 12;133(40):16146-53 [21882887.001]
  • [Cites] Angew Chem Int Ed Engl. 2012 Jan 2;51(1):250-3 [22095623.001]
  • [Cites] Clin Cancer Res. 2012 Mar 1;18(5):1268-80 [22230766.001]
  • [Cites] J Am Chem Soc. 2012 Mar 21;134(11):5157-64 [22372563.001]
  • [Cites] Chem Commun (Camb). 2012 Nov 11;48(87):10739-41 [23012694.001]
  • [Cites] Nat Rev Genet. 2012 Nov;13(11):770-80 [23032257.001]
  • [Cites] Nat Chem. 2013 Mar;5(3):182-6 [23422559.001]
  • [Cites] Nat Struct Mol Biol. 2013 Mar;20(3):396-403 [23416947.001]
  • [Cites] J Am Chem Soc. 2014 Mar 19;136(11):4172-85 [24559432.001]
  • [Cites] Nucleic Acids Res. 2014 May;42(9):5755-64 [24609386.001]
  • [Cites] Nucleic Acids Res. 2006;34(18):5133-44 [16998187.001]
  • [Cites] J Am Chem Soc. 2007 Oct 31;129(43):12926-7 [17918848.001]
  • [Cites] J Pathol. 2005 Jun;206(2):123-34 [15880597.001]
  • [Cites] Nucleic Acids Res. 2005;33(9):2908-16 [15914667.001]
  • [Cites] Blood. 2005 Jul 15;106(2):408-18 [15797997.001]
  • [Cites] Biochemistry. 2005 Dec 13;44(49):16341-50 [16331995.001]
  • [Cites] Nucleic Acids Res. 2006;34(9):2536-49 [16687659.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Dec 26;103(52):19658-63 [17167055.001]
  • [Cites] Nucleic Acids Res. 2007;35(22):7698-713 [17984069.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):880-9 [18413801.001]
  • [Cites] Org Lett. 2008 Jun 5;10(11):2127-30 [18444656.001]
  • [Cites] Biochimie. 2008 Aug;90(8):1149-71 [18355457.001]
  • [Cites] Nucleic Acids Res. 2008 Aug;36(14):4598-608 [18614607.001]
  • [Cites] Nucleic Acids Res. 2008 Nov;36(19):6260-8 [18832370.001]
  • [Cites] Nucleic Acids Res. 2009 Jan;37(1):172-83 [19033359.001]
  • [Cites] J Med Chem. 2009 May 14;52(9):2863-74 [19385599.001]
  • [Cites] J Biol Chem. 2009 Aug 28;284(35):23622-35 [19581307.001]
  • [Cites] J Am Chem Soc. 2009 Aug 12;131(31):10878-91 [19601575.001]
  • [Cites] Blood Cells Mol Dis. 2001 Jan-Feb;27(1):206-16 [11358381.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11593-8 [12195017.001]
  • [Cites] Arch Virol. 2004 Feb;149(2):289-302 [14745596.001]
  • [Cites] Proc Natl Acad Sci U S A. 1979 Jan;76(1):24-8 [284337.001]
  • [Cites] Nature. 1988 Sep 29;335(6189):440-2 [3262202.001]
  • [Cites] Nature. 1993 Jun 10;363(6429):561-5 [8389423.001]
  • [Cites] Ann Oncol. 1994;5 Suppl 1:61-5 [8172820.001]
  • [Cites] J Cell Biochem. 1996 Jan;60(1):23-32 [8825412.001]
  • [Cites] Hematol Oncol. 1996 Jun;14(2):67-82 [8876636.001]
  • [Cites] Nat Rev Cancer. 2009 Dec;9(12):849-61 [19907434.001]
  • (PMID = 24559410.001).
  • [ISSN] 1520-5126
  • [Journal-full-title] Journal of the American Chemical Society
  • [ISO-abbreviation] J. Am. Chem. Soc.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32CA09213; United States / NIGMS NIH HHS / GM / GM085585-02S1; United States / NIGMS NIH HHS / GM / R01 GM083117; United States / NCI NIH HHS / CA / R01 CA122952; United States / NCI NIH HHS / CA / CA153821; United States / NIGMS NIH HHS / GM / GM083117; United States / NIGMS NIH HHS / GM / GM085585-01; United States / NCI NIH HHS / CA / R01 CA153821; United States / NIGMS NIH HHS / GM / R01 GM085585
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Piperidines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / RNA, Messenger; 9007-49-2 / DNA; JR3JD1Y22C / Pregnanediol
  • [Other-IDs] NLM/ NIHMS571045; NLM/ PMC3985915
  •  go-up   go-down






Advertisement